These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 31062492)

  • 1. Specificity, strength, and evolution of pretransplant donor-specific HLA antibodies determine outcome after kidney transplantation.
    Senev A; Lerut E; Van Sandt V; Coemans M; Callemeyn J; Sprangers B; Kuypers D; Emonds MP; Naesens M
    Am J Transplant; 2019 Nov; 19(11):3100-3113. PubMed ID: 31062492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histological picture of antibody-mediated rejection without donor-specific anti-HLA antibodies: Clinical presentation and implications for outcome.
    Senev A; Coemans M; Lerut E; Van Sandt V; Daniëls L; Kuypers D; Sprangers B; Emonds MP; Naesens M
    Am J Transplant; 2019 Mar; 19(3):763-780. PubMed ID: 30107078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A personalised delisting strategy enables successful kidney transplantation in highly sensitised patients with preformed donor-specific anti HLA antibodies.
    García-Jiménez S; Paz-Artal E; Trujillo H; Polanco N; Castro MJ; Del Rey MJ; Alfocea Á; Morales E; González E; Andrés A; Mancebo E
    HLA; 2024 Jun; 103(6):e15572. PubMed ID: 38923242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value of monitoring circulating donor-reactive memory B cells to characterize antibody-mediated rejection after kidney transplantation.
    Luque S; Lúcia M; Melilli E; Lefaucheur C; Crespo M; Loupy A; Bernal-Casas D; Gomà M; Jarque M; Crespo E; Montero N; Manonelles A; Cruzado JM; Gil-Vernet S; Grinyó JM; Bestard O
    Am J Transplant; 2019 Feb; 19(2):368-380. PubMed ID: 30085394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-mediated rejection with and without donor-specific anti-human leucocyte antigen antibodies: performance of the peripheral blood 8-gene expression assay.
    Van Loon E; Lerut E; de Loor H; Kuypers D; Emonds MP; Anglicheau D; Gwinner W; Essig M; Marquet P; Naesens M
    Nephrol Dial Transplant; 2020 Aug; 35(8):1328-1337. PubMed ID: 32594133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of donor-specific HLA antibodies in living versus deceased donor transplant.
    Kamburova EG; Wisse BW; Joosten I; Allebes WA; van der Meer A; Hilbrands LB; Baas MC; Spierings E; Hack CE; van Reekum FE; van Zuilen AD; Verhaar MC; Bots ML; Drop ACAD; Plaisier L; Seelen MAJ; Sanders JSF; Hepkema BG; Lambeck AJA; Bungener LB; Roozendaal C; Tilanus MGJ; Voorter CE; Wieten L; van Duijnhoven EM; Gelens M; Christiaans MHL; van Ittersum FJ; Nurmohamed SA; Lardy NM; Swelsen W; van der Pant KA; van der Weerd NC; Ten Berge IJM; Bemelman FJ; Hoitsma A; van der Boog PJM; de Fijter JW; Betjes MGH; Heidt S; Roelen DL; Claas FH; Otten HG
    Am J Transplant; 2018 Sep; 18(9):2274-2284. PubMed ID: 29464832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deceased donor kidney transplantation across donor-specific antibody barriers: predictors of antibody-mediated rejection.
    Schwaiger E; Eskandary F; Kozakowski N; Bond G; Kikić Ž; Yoo D; Rasoul-Rockenschaub S; Oberbauer R; Böhmig GA
    Nephrol Dial Transplant; 2016 Aug; 31(8):1342-51. PubMed ID: 27190362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Shared alloimmune responses against blood and transplant donors result in adverse clinical outcomes following blood transfusion post-renal transplantation.
    Hassan S; Regan F; Brown C; Harmer A; Anderson N; Beckwith H; Roufosse CA; Santos-Nunez E; Brookes P; Taube D; Willicombe M
    Am J Transplant; 2019 Jun; 19(6):1720-1729. PubMed ID: 30582278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allocation to highly sensitized patients based on acceptable mismatches results in low rejection rates comparable to nonsensitized patients.
    Heidt S; Haasnoot GW; Witvliet MD; van der Linden-van Oevelen MJH; Kamburova EG; Wisse BW; Joosten I; Allebes WA; van der Meer A; Hilbrands LB; Baas MC; Spierings E; Hack CE; van Reekum FE; van Zuilen AD; Verhaar MC; Bots ML; Drop ACAD; Plaisier L; Seelen MAJ; Sanders JS; Hepkema BG; Lambeck AJA; Bungener LB; Roozendaal C; Tilanus MGJ; Voorter CE; Wieten L; van Duijnhoven EM; Gelens MACJ; Christiaans MHL; van Ittersum FJ; Nurmohamed SA; Lardy NM; Swelsen W; van der Pant KAMI; van der Weerd NC; Ten Berge IJM; Bemelman FJ; Hoitsma A; van der Boog PJM; de Fijter JW; Betjes MGH; Otten HG; Roelen DL; Claas FHJ
    Am J Transplant; 2019 Oct; 19(10):2926-2933. PubMed ID: 31155833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kidney Intragraft Homing of De Novo Donor-Specific HLA Antibodies Is an Essential Step of Antibody-Mediated Damage but Not Per Se Predictive of Graft Loss.
    Nocera A; Tagliamacco A; Cioni M; Innocente A; Fontana I; Barbano G; Carrea A; Ramondetta M; Sementa A; Basso S; Quartuccio G; Klersy C; Bertocchi M; Verrina E; Garibotto G; Ghiggeri GM; Cardillo M; Comoli P; Ginevri F
    Am J Transplant; 2017 Mar; 17(3):692-702. PubMed ID: 27501275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Significance of Pretransplant Donor-Specific Antibodies in the Setting of Negative Cell-Based Flow Cytometry Crossmatching in Kidney Transplant Recipients.
    Adebiyi OO; Gralla J; Klem P; Freed B; Davis S; Wiseman AC; Cooper JE
    Am J Transplant; 2016 Dec; 16(12):3458-3467. PubMed ID: 27140940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preformed Donor-Specific HLA Antibodies in Living and Deceased Donor Transplantation: A Multicenter Study.
    Ziemann M; Altermann W; Angert K; Arns W; Bachmann A; Bakchoul T; Banas B; von Borstel A; Budde K; Ditt V; Einecke G; Eisenberger U; Feldkamp T; Görg S; Guthoff M; Habicht A; Hallensleben M; Heinemann FM; Hessler N; Hugo C; Kaufmann M; Kauke T; Koch M; König IR; Kurschat C; Lehmann C; Marget M; Mühlfeld A; Nitschke M; Pego da Silva L; Quick C; Rahmel A; Rath T; Reinke P; Renders L; Sommer F; Spriewald B; Staeck O; Stippel D; Süsal C; Thiele B; Zecher D; Lachmann N
    Clin J Am Soc Nephrol; 2019 Jul; 14(7):1056-1066. PubMed ID: 31213508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of low pre-transplant donor specific antibodies (DSA) in living donor kidney recipients with negative complement-dependent cytotoxicity crossmatches (CDCXM), and negative flow cytometry crossmatches (FLXM) - A single-center experience.
    Olszowska-Zaremba N; Gozdowska J; Zagożdżon R
    Transpl Immunol; 2022 Oct; 74():101672. PubMed ID: 35868613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of pretransplant donor-specific antibodies on kidney allograft recipients with negative flow cytometry cross-matches.
    Kwon H; Kim YH; Choi JY; Shin S; Jung JH; Park SK; Han DJ
    Clin Transplant; 2018 Jun; 32(6):e13266. PubMed ID: 29676812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Donor Specificity but Not Broadness of Sensitization Is Associated With Antibody-Mediated Rejection and Graft Loss in Renal Allograft Recipients.
    Wehmeier C; Hönger G; Cun H; Amico P; Hirt-Minkowski P; Georgalis A; Hopfer H; Dickenmann M; Steiger J; Schaub S
    Am J Transplant; 2017 Aug; 17(8):2092-2102. PubMed ID: 28245084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical utility of complement-dependent C3d assay in kidney recipients presenting with late allograft dysfunction.
    Lan JH; Gjertson D; Zheng Y; Clark S; ; Reed EF; Cecka MJ
    Am J Transplant; 2018 Dec; 18(12):2934-2944. PubMed ID: 29659162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of de novo IgM and IgG anti-HLA DSAs between belatacept- and calcineurin-treated patients: An analysis of the BENEFIT and BENEFIT-EXT trial cohorts.
    Everly MJ; Roberts M; Townsend R; Bray RA; Gebel HM
    Am J Transplant; 2018 Sep; 18(9):2305-2313. PubMed ID: 29767445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in-patient phase 1 trial.
    Eskandary F; Jilma B; Mühlbacher J; Wahrmann M; Regele H; Kozakowski N; Firbas C; Panicker S; Parry GC; Gilbert JC; Halloran PF; Böhmig GA
    Am J Transplant; 2018 Apr; 18(4):916-926. PubMed ID: 28980446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical importance of extended second field high-resolution HLA genotyping for kidney transplantation.
    Senev A; Emonds MP; Van Sandt V; Lerut E; Coemans M; Sprangers B; Kuypers D; Naesens M
    Am J Transplant; 2020 Dec; 20(12):3367-3378. PubMed ID: 32337773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Low-Level Donor-Specific Anti-HLA Antibody on Posttransplant Clinical Outcomes in Kidney Transplant Recipients.
    Lee H; Lee H; Eum SH; Ko EJ; Min JW; Oh EJ; Yang CW; Chung BH
    Ann Lab Med; 2023 Jul; 43(4):364-374. PubMed ID: 36843405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.